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57 ABSTRACT 
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The government owns rights in the present invention 
pursuant to NIH grants AI 28845 and AI 33577. 
This application is a continuation-in-part application of 5 
U.S. Ser. No. 07/964,607, filed Oct. 21, 1992, now U.S. Pat. 
No. 5,457,195, which reference is incorporated by reference 
herein. 
BACKGROUND OF THE INVENTION 10 
1. Field of the Invention 
The present invention relates generally to sapphyrin mul 
timers, and derivatives and conjugates thereof. The multi 
mers include dimers, trimers, oligomers and polymers of 15 
sapphyrin or sapphyrin derivatives, either alone, or in com 
bination with other units such as nucleobases. 
2. Description of the Related Art 
Sapphyrins are large pyrrole-containing macrocyclic ana 
logues of the porphyrins. A number of expanded porphyrin 20 
systems are now known. However, only a few fully conju 
gated examples have been reported that contain more than 
four pyrrolic subunits, namely the smaragdyrins, sapphyrins, 
pentaphyrins, hexaphyrins, and superphthalocyanines' 
(Sessler & Burrel, 1991). 25 
Sapphyrin, first discovered serendipitously by Wood 
ward is one of the more intriguing products to emerge from 
initial studies directed towards the synthesis of Vitamin 
B2.’ It is a 22 pi-electron pentapyrrolic macrocycle which 
exhibits an intense Soret-like band at about 450 nm (CHCl) 
along with weaker Q-type transitions in the 620 to 690 nm. 
region. These optical properties, along with the presence of 
a large central cavity which serves for metal binding, renders 
sapphyrin useful for certain biomedical applications, includ 
ing photodynamic therapy (PDT) and magnetic resonance 
imaging enhancement (MRI). 
In addition to the above, certain expanded porphyrins, 
including especially those of the sapphyrin series, have been 
found to act as halide anion chelating agents in both solution 
and the solid state'. This finding, along with an appreciation 
that the diprotonated form of 3,8,12,13,17,22-hexaethyl-2, 
7,18,23-tetramethylsapphyrin acts as an efficient carrier for 
the through-dichloromethane-membrane transport of nucle 
otide monophosphates, such as e.g. guanosine-5' monophos 
phate, and related entities at acidic pH led the inventors to 
consider that the basic sapphyrin structure and related com 
pounds such as the rubyrins, if suitably modified, could be 
used to bind, recognize, and transport phosphorylated enti 
ties at or near neutral pH. 
Unfortunately, all sapphyrins known at the time of this 
invention were known both to be essentially insoluble in 
water and also known to be ineffective as through membrane 
carriers for phosphate monoesters including those specifi 
cally that define the class of compounds known as nucle- 55 
otides and nucleotide analogues. In addition, the sapphyrins 
known prior to the present invention were all of such simple 
character in terms of peripheral substituents, such that only 
hydrogen or alkyl were known. These deficiencies limited 
the potential utility of sapphyrins for any applications asso- 60 
ciated with their use at or near neutral pH and, more 
generally, any conditions involving partial or complete asso 
ciation with an aqueous environment. 
At present, no general set of nucleotide transport agents 
exists'. In early work Tabushi was able to effect adenosine 65 
nucleotide transport using a lipophilic, diazabicyclooctane 






system failed to mediate the transport of guanosine 5'-mono 
phosphate (GMP) or other guanosine-derived nucleotides. 
Since then, considerable effort has been devoted to the 
generalized problem of nucleic acid base ("nucleobase') 
recognition, and various binding systems have been 
reported. 
Currently known nucleotide binding systems include vari 
ous acyclic, macrocyclic, and macrobicyclic polyaza 
systems''"; nucleotide-binding bis-intercalands'; 
guanidinium-based receptors'"; and various rationally 
designed H-bonding receptors''. These latter H-bond 
ing receptors have been shown to be effective for the 
chelation of neutral nucleobase and/or nucleoside derived 
substrates but, without exception, have all proved unsatis 
factory for the important task of charged nucleotide recog 
nition. Thus, despite intensive efforts in this field, there is 
currently no synthetic system capable of effecting the rec 
ognition, or through-membrane transport, of phosphate 
bearing species such as anti-viral compounds. Furthermore, 
there are presently no rationally designed receptors which 
are "tunable' for the selective complexation of a given 
nucleobase-derived system. 
Not surprisingly, the transport of larger polyphosphory 
lated compounds across cellular membranes also poses 
significant problems. The difficulties in transporting oligo 
nucleotides across the plasma membrane and into mamma 
lian cells is one of the factors currently limiting the suc 
cessful application of antisense technology to human 
therapy. Further limitations may also result from the dynam 
ics of oligonucleotide recognition, binding and functional 
inhibition which occurs intracellularly, subsequent to any 
import that does occur. 
There is clearly, therefore, a major need for novel drug 
delivery systems to be developed. Compounds which would 
allow negatively-charged (anionic) structures, particularly 
phosphate-bearing compounds, including nucleotides and 
nucleotide derivatives such as anti-viral compounds and 
anti-sense oligonucleotides, to be transported across natu 
rally lipophilic cellular membranes would represent an 
important scientific and medical advance. 
In addition to the delivery of compounds to cells, there 
still remains considerable scope for the design of improved 
chemotherapeutic compounds which act upon DNA once 
inside a target cell. Since currently available chemothera 
peutic agents have complex structures, or complicated 
modes of interaction with their targets that preclude system 
atic improvement, the development of a novel class of DNA 
binding compounds would open up new avenues for the 
design of improved therapeutics. In this regard, a class of 
compounds that can be modified in a number of different 
ways while maintaining their overall oligomeric, or poly 
meric structure would be particularly advantageous. The 
same is true for compounds that can be activated by light, or 
other means, to produce singlet oxygen or hydroxyl radicals, 
once bound to DNA. These considerations provided the 
present inventors with further impetus for the design and 
synthesis of improved sapphyrins such as those embodied by 
the present invention. 
SUMMARY OF THE INVENTION 
The present invention addresses these and other short 
comings in the prior art through the synthesis of several 
multimers of sapphyrin or sapphyrin derivatives. In a gen 
eral and overall sense, included within the novel compounds 
of the invention are sapphyrin dimers, trimers, oligomers 
5,587.478 
3 
and polymers. Multimers will typically comprise sapphyrin 
or sapphyrin derivatives alone, or sapphyrin in combination 
with other units such as nucleobases, as well as complexes 
of sapphyrin-nucleobase polymers with oligonucleotides, 
for example. 
In general terms, sapphyrin multimers of the present 
invention can be defined by the following general structure: 
R9 I 
wherein each of R'-R'' are independently hydrogen, alkyl, 
alkene, alkyne, halide, alkylhalide, hydroxyalkyl, hydroxy 
alkylamido, glycol, polyglycol, thiol, thioalkyl, aminoalkyl, 
carboxyalkyl, carboxyamidealkyl, oxyalkyl, alkoxyalkyl, 
aryloxyalkyl, oxyhydroxyalkyl, alkyloxycarbonyl, aryloxy 
carbonyl, aldehyde, ether, ketone, carboxylic acid, phos 
phate, phosphonate, saccharide, nucleobase, sulfate, phos 
phate substituted alkyl, phosphonate substituted alkyl or 
sulfate substituted alkyl, such that the total number of carbon 
atoms in each substituent R is less than or equal to 10,000. 
R5 R16 R17 R18 
R10 
R12 Rll 
In this general sapphyrin multimer structure, at least one 
of R'-R' is of the formula (CH)-A-(CH2)-B; 
where A is alkyl, oxy, sulfide, amide, carbonyl, alkenyl, 
alkynyl, aryl, alkylhalide, hydroxyalkyl, glycol, polyglycol, 
alkylthiol, substituted alkyl, phosphate, phosphonate, sul 
fate, phosphate substituted alkyl, phosphonate substituted 
alkyl, sulfate substituted alkyl, carbonate, carbamate, 
bis(aminoguanidinium), carboxy, carboxyamide, carboxya 
midealkyl, carboxyamidearyl, thiol-substituted carboxya 
mide, or derivatized carboxyamide; and B is a sapphyrin or 
a sapphyrin derivative, or an oligomer or polymer of sap 
phyrin or of a sapphyrin derivative; and n and m are 
independently an integer from 0 to 10. 
The novel aspect of the foregoing structure is the fact that 
in the context of the present invention, at least one R group 
substituent will be of the general formula X-B, wherein X is 
any Sapphyrin compound and B is another sapphyrin or 
sapphyrin derivative, or is a polymer or oligomer of sap 











as used herein refers to any derivative or conjugate of 
sapphyrin including, but not limited to, alkyl and carboxy 
alkyl sapphyrins, water-soluble sapphyrins such as sapphy 
rin-sugar compounds and polyhydroxysapphyrins, Sapphy 
rin-metal chelator conjugates, and Sapphyrin-nucleobase 
conjugates. 
The B substituent can include any sapphyrin, sapphyrin 
derivative, polysapphyrin, or oligosapphyrin. Conjugation 
of further derivatives to form a sapphyrin oligomer or 
polymer may be via any of the R groups R-R', with R', 
RandR, being preferred targets. Conjugation at more than 
one point is also contemplated and may be via any two, or 
more, of the R groups R-R', such as RandR', RandR, 
or R and R, for example 
As used herein, the terms "sapphyrin multimer' and 
"multimer of sapphyrin' are intended to refer to any com 
pound which includes at least two sapphyrin macrocycles 
joined covalently by a linking group. Moreover, the term 
'sapphyrin oligomer' or "oligosapphyrin' is intended to 
refer to sapphyrin-containing structures having a more 
defined length, such as from 2 or 3 up to 20 or so sapphyrin 
units/molecule and the term "sapphyrin polymer' or 
"polysapphyrin' is intended to refer to sapphyrin-containing 
structures having up to about 200 sapphyrin units/molecule. 
Preferably, a sapphyrin polymer has about 30-60 sapphyrin 
units. 
Structure II represents the general structure for the 
dimeric sapphyrins of this invention, and is an example of 
structure I, wherein a further sapphyrin derivative has been 
added. Structure II includes R-R' each R group may be 
independently any of the groups listed above for R-R', 
and also 'A', which is as herein defined. 
STRUCTURE I 
R5 
Structure III represents the general structure for the poly 
meric sapphyrins of the present invention. Structure III is a 
more specific polymeric example of both structures I and II, 
wherein further sapphyrin derivatives or other moieties, 
such as oligonucleotides or sapphyrin-oligonucleotides, 
have been added. In structure III, t may be from 1-100, or 





Preferred sapphyrin multimers are: i) wherein A is car 
boxyamidearyl or carboxyamidealkyl, B is a sapphyrin or a 
sapphyrin derivative, and n and m are independently 1, 2 or 
3; ii) wherein B is a sapphyrin derivative and the sapphyrin 
derivative is hydroxyalkyl, saccharide or aminosaccharide 
derivative; iii) wherein A is carboxyamidealkyl bound to a 
further amide; and the further amide is covalently bound to 
two molecules of B to form a tethered sapphyrin trimer; iv) 
wherein B is sapphyrin or sapphyrin derivative and B is 
further bound to a third sapphyrin or sapphyrin derivative to 
form a linear sapphyrin trimer; v) wherein the abovenamed 
linear sapphyrin trimer is covalently bound to form a cyclic 
trimer; vi) wherein A is carboxyamidealkyl bound to a 
further amide; the further amide being covalently bound to 
a second sapphyrin and a linker, the linker being bound to a 
third and a fourth sapphyrin to form a tethered sapphyrin 
tetramer, vii) the abovenamed tetramer where the linker is a 
tertiary amine; viii) wherein B is an oligomer or polymer of 
sapphyrin or sapphyrin derivative; ix) wherein B is a poly 
mer of sapphyrin or sapphyrin derivative having from 4 to 
about 200 sapphyrin units; x) wherein A is phosphate; xi) 
wherein at least one of R-R' is a nucleobase; xii) where 
B is a sapphyrin derivative and the derivative is a nucleo 
base; xiii) wherein B is a polymer of sapphyrin derivative 
and the derivative is a nucleobase; or xiv) a sapphyrin 
multimer further comprising a noncovalently bound oligo 
nucleotide. 
Particularly preferred sapphyrin multimers are those of 
structure 14, 15, 15b, 15c, 19, 21, 22, 23, 24, 25, 26, 27, 34, 
35, or 36. 
A further embodiment of the present invention is a 
method of making a sapphyrin multimer comprising the 
steps of i) obtaining a sapphyrin or sapphyrin derivative, and 
ii) reacting the sapphyrin or sapphyrin derivative with a 
further sapphyrin or sapphyrin derivative to form a sapphy 
rin multimer. Preferred multimers are dimers; a tethered, 
linear, or cyclic trimer, a tethered tetramer; an oligomer of 
about 2-20 sapphyrin units, or a polymer of about 3 to 200 
sapphyrin units, preferably about 30-60 sapphyrin units. 
It is contemplated that stepwise synthesis of sapphyrin 
multimer-oligonucleotide conjugates may be performed 
manually or may be automated, and may be in a solution 
phase or on a solid support. Solid support synthesis may be 
accomplished using an automated or a manual nucleic acid 
synthesizer. Common solid supports are CPG (control pore 
glass) and CPS (control pore silica). Other possible solid 
supports include polystyrene, polyamide/Kieselguhr, and 
cellulose paper. A preferred embodiment of this method is 
automated synthesis on a solid support. Attachment of a 
sapphyrin multimer to an oligonucleotide during stepwise 
synthesis obviates the need for a postmodification protocol 
and a second purification of the product. This results in an 












Another aspect of the present invention is a method of 
binding an anion comprising the step of contacting the anion 
with a multimeric sapphyrin or sapphyrin derivative. The 
anion is preferably a phosphate or dicarboxylate anion. 
Protonated Sapphyrin dimers are demonstrated herein to act 
as effective receptors for certain dicarboxylate anions. The 
sapphyrin molecule itself remains monoprotonated in the pH 
range of about 3.5-10. A high selectivity was demonstrated 
for benzenedicarboxylate anions, especially the paraisomer. 
One skilled in the artin light of this disclosure would realize 
that multiple molecules of dicarboxylate anion may be 
bound by a sapphyrin multimer. A variety of physiologically 
important dianion species may, therefore, be bound and 
detected and/or transported by sapphyrin multimers, includ 
ing fatty acids, and phosphates, for example. 
A further aspect of the present invention is a method of 
transporting an anion from a source to a receiving phase, the 
method comprising the steps of: i) obtaining an anion in a 
source; and ii) contacting the anion with a protonated 
multimer of sapphyrin or sapphyrin derivative as described 
herein above, wherein the multimer releases the anion to the 
receiving phase. The anion is preferably a dicarboxylate 
anion, and more preferably, a benzenedicarboxylate anion, 
and even more preferably, a para isomer of a benzene 
dicarboxylate anion. 
It will be appreciated by those of skill in the art that the 
invention is also generally applicable to the introduction of 
a sapphyrin multimer, alone or complexed with a second 
molecule, into an organism or, more generally, a cell con 
tained within an organism. This may be employed as a 
means, for example, of successfully introducing the second 
compound (typically a charged compound) into the cell. An 
example might be introduction of a complex which includes 
an antimetabolic or antienzymatic compound such as an 
antiviral antimetabolic or antienzymatic compound, which 
one desires to introduce into a virally infected target cell. 
Another example would be the introduction of an antime 
tabolic or antienzymatic antitumor or antiproliferative com 
pound that is introduced into a targeted tumor or prolifer 
ating cell. Of course, it is contemplated that the target cell 
may be located within an animal or human patient, in which 
case the complex is administered in effective amounts in an 
effective manner to the patient. 
Generally speaking, it is contemplated by the inventors 
that useful pharmaceutical compositions of the present 
invention will include the selected sapphyrin multimer 
(which preferably incorporates a water-soluble sapphyrin 
macrocycle) in a therapeutically effective amount that is 
diluted in a physiological buffer, such as phosphate buffered 
saline. The route of administration and ultimate amount of 
material that is administered to the patient or animal under 
such circumstances will depend upon the intended applica 
tion and will be apparent to those of skill in the art in light 
of the examples which follow. Preferred routes of adminis 
tration will typically include parenteral or topical routes. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 provides a schematic representation of the pro 
posed supramolecular complex formed between a sapphyrin 
dimer and a dicarboxylate substrate. 
DETALED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
The synthesis of various sapphyrins has been previously 
reported?'', see also, U.S. Pat. Nos. 5,159,065, 5,120, 
411, 5,041,078, 5,302,714, and U.S. Ser. No. 07/964,607; 
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each of these references is incorporated herein by reference. 
The present invention concerns a variety of new sapphyrin 
based systems, in which the sapphyrin molecule has been 
"multimerized' in a number of novel ways. In particular, this 
invention encompasses dimeric, trimeric, oligomeric and 5 
polymeric sapphyrin multimers. Such sapphyrin multimers 
may comprise water-soluble sapphyrins, sapphyrin-metal 
chelator conjugates or Sapphyrin-nucleobase conjugates. 
These new sapphyrin species overcome known deficien 
cies associated with extant sapphyrins. This is because all 10 
sapphyrins known at the time of this invention were exclu 
sively monomeric in nature and insoluble in aqueous media 
at or near neutral pH. Thus, the sapphyrins known prior to 
the present invention were incapable of forming well char 
acterized, water-soluble complexes with phosphorylated 15 
entities, including DNA, RNA, nucleotides, nucleotide ana 
logues, and simple phosphate and phosphonate monoesters, 
at or near neutral pH. Multimeric sapphyrins were unknown. 
In addition, all sapphyrins known at the time of this 
invention were recognized to be quite limited in terms of 
their substitution patterns, bearing only alkyl groups in the 
so-called 3-positions. Furthermore, this same lack of sub 
stituent versatility meant that sapphyrin systems carrying 
potentially reactive side chains were completely unknown 
and this too was recognized as limiting the utility of those 
few sapphyrins known to be extant at the time of this 
invention. Thus, the inventors felt it worthwhile to prepare 
oligomeric and polymeric sapphyrin systems, wherein the 
binding and recognition effects achieved in the monomeric 
sapphyrins might be expected to be greatly amplified. 
Representative examples of alkanes useful as alkyl group 
substituents of sapphyrin oligomers or polymers include 
methane, ethane, straight-chain, branched or cyclic isomers 
of propane, butane, pentane, hexane, heptane, octane, 
nonane and decane, with methane, ethane and propane being 
preferred. Representative examples of alkenes useful as 
alkenyl group substituents include ethene, straight-chain, 
branched or cyclic isomers of propene, butene, pentene, 
hexene, heptene, octene, nonene and decene, with ethene 
and propene being preferred. Representative examples of 
alkynes useful as alkynyl group substituents include ethyne, 
straight-chain, branched or cyclic isomers of propyne, 
butyne, pentyne, heXyne, heptyne, octyne, nonyne and 
decyne, with ethyne and propyne being preferred. Repre 
sentative examples of substituted alkyls include alkyls sub 
stituted by one or more functional groups as described 
herein. 
Among the halide substituents, chloride, bromide, fluo 
ride and iodide are contemplated in the practice of this 50 
invention. Representative examples of alkylhalides used in 
this invention include halides of methane, ethane, propane, 
butane, pentane, hexane, heptane, octane, nonane and 
decane, with halides, preferably chlorides or bromides, of 
methane, ethane and propane being preferred. 55 
Representative examples of hydroxyalkyls include alco 
hols of methane, ethane; straight-chain, branched or cyclic 
isomers of propane, butane, pentane, hexane, heptane, 
octane, nonane and decane, with alcohols of methane, 
ethane or propane being preferred. "Hydroxyalkyl' is meant 60 
to include glycols and polyglycols; diols of ethane, straight 
chain, branched or cyclic isomers of propane, butane, pen 
tane, hexane, heptane, octane, nonane and decane, with diols 
of ethane or propane being preferred; polyethylene glycol, 
polypropylene glycol and polybutylene glycol as well as 65 
polyalkylene glycols containing combinations of ethylene, 








Representative examples of oxyalkyls include the alkyl 
groups as herein described having ether linkages. The num 
ber of repeating oxyalkyls within a substituent may be up to 
100, preferably is from 1-10, and more preferably, is 2-3. A 
preferred oxyalkyl is O(CH2CH2O), CH, where x=1-100, 
preferably 1-10, and more preferably, 2-3. 
Representative examples of thioalkyls include thiols of 
ethane, thiols of straight-chain, branched or cyclic isoners 
of propane, butane, pentane, hexane, heptane, octane, 
nonane and decane, with thiols of ethane (ethanethiol, 
CHSH) or propane (propanethiol, CHSH) being pre 
ferred. Sulfate substituted alkyls include alkyls as described 
above substituted by one or more sulfate groups, a repre 
sentative example of which is diethyl sulfate ((CH3)2SO). 
Representative examples of phosphates include phosphate 
or polyphosphate groups. Representative examples of phos 
phate substituted alkyls include alkyls as described above 
substituted by one or more phosphate or polyphosphate 
groups. Representative examples of phosphonate substituted 
alkyls include alkyls as described above substituted by one 
or more phosphonate groups. 
Representative examples of carboxy groups include car 
boxylic acids of the alkyls described above as well as aryl 
carboxylic acids such as benzoic acid. Representative 
examples of carboxyamides include primary carboxyamides 
(CONH), secondary (CONHR) and tertiary (CONRR") 
carboxyamides where each of R and R" is a functional 
group as described herein. 
Representative examples of useful amines include a pri 
mary, secondary or tertiary amine of an alkyl as described 
hereinabove. Hydroxyalkylamido refers to a substituent 
having a hydroxyalkyl and an amine group, the amine may 
be primary, secondary or tertiary. 
“Hydroxyalkyl' means alkyl groups having hydroxyl 
groups attached. "Oxyalkyl' means alkyl groups attached to 
an oxygen. "Oxyhydroxyalkyl' means alkyl groups having 
ether or ester linkages, hydroxyl groups, substituted 
hydroxyl groups, carboxyl groups, substituted carboxyl 
groups or the like. "Saccharide' includes oxidized, reduced 
or substituted saccharide of Table 1, for example; saccha 
rides such as in Table 1, derivatives such as acetals, amines, 
and phosphorylated sugars, oligosaccharides, as well as 
open chain forms of various sugars, and the like. Examples 
of amine-derivatized sugars are galactosamine, glu 
cosamine, sialic acid and D-glucamine derivatives such as 
1-amino-1-deoxysorbitol. The saccharides employed may be 
either D or L forms and may also be eithero or B forms. The 
use of modified saccharides is also envisioned, such as those 
including, for example, phosphate, methyl or amino groups. 
It is contemplated that preferred saccharides for use in 
accordance herewith will include, for example, glucose, 
glucosamine, galactose, galactosamine and mannose. 
"Carboxyamidealkyl" means alkyl groups with hydroxyl 
groups, secondary or tertiary amide linkages or the like. 
Carboxyalkyl means alkyl groups having hydroxyl groups, 
carboxyl or amide substituted ethers, ester linkages, tertiary 
amide linkages removed from the ether or the like. 
For the sapphyrins of the present invention, oxyhydroxy 
alkyl may be alkyl having independently hydroxy substitu 
ents and ether branches or may be Co-Ho-1 O.O, or 
OCH22O,O, where n is a positive integer from 1 
to 10, X is Zero or a positive integer less than or equal to n, 
and y is Zero or a positive integer less than or equal to 
The oxyhydroxyalkyl or saccharide may be 
C.Ho-1-OROCH(21-OR or (CH2)CO2R 
5,587.478 
9 
where n is a positive integer from 1 to 10, y is zero or a 
positive integer less than (2n+1)-q) q is zero or a positive 
integer less than or equal to 2n+1, R is independently H, 
alkyl, hydroxyalkyl, Saccharide, Co-Ho-1-2O, O, 
O2CCon-w)Hom-1-2O.O. O 
N(R)OCCH2n-2O, O, where m is a positive inte 
ger from 1 to 10, w is zero or a positive integer less than or 
equal to m, Z is Zero or a positive integer less than or equal 
to ((2m+1)-2w), R is H alkyl, hydroxyalkyl, or 
CnHomOR, where m is a positive integer from 1 to 
10, Z is zero or a positive integer less than ((2m+1)-r), r is 
zero or a positive integer less than or equal to 2m+1, and R' 
is independently H, alkyl, hydroxyalkyl, or saccharide. 
Carboxyamidealkyl may be alkyl having secondary or 
tertiary amide linkages or (CH),CONHR, 
O(CH),CONHR, (CH2)CONCR), O 
O(CH2)CONCR), where n is a positive integer from 1 to 
10, R is independently H, alkyl, hydroxyalkyl, saccharide, 
Co-Hom:19-2O.O. O2CCon-w)Hom:19-2O.O. or 
N(R)OCCH21 200 where mis a positive inte 
ger from 1 to 10, w is zero or a positive integer less than or 
equal to m, Z is zero or a positive integer less than or equal 
to ((2m+1)-2w), R is H, alkyl, hydroxyalkyl, or 
CHOR, where m is a positive integer from 1 to 
10, Z is zero or a positive integer less than ((2m+1)-r), r is 
zero or a positive integer less than or equal to 2m+1, and R' 
is independently H, alkyl, hydroxyalkyl, or saccharide. 
The carboxyalkyl may be alkyl having a carboxyl substi 
tuted ether, an amide substituted ether or a tertiary amide 
removed from an ether or CH2--OR or 
OCHOR where n is a positive integer from 1 to 
10; y is Zero or a positive integer less than ((2n+1)-q), q is 
Zero or a positive integer less than or equal to 2n+1, R is 
(CH2)COR, (CH),CONHR or (CH),CONCR), where 
n is a positive integer from 1 to 10; R is independently H, 
alkyl, hydroxyalkyl, saccharide, Co-Ho-1-2O, O, 
O2CCon-whom 1-2O.O. O 
N(R)OCCH2O, O, where m is a positive inte 
ger from 1 to 10, w is zero or a positive integer less than or 
equal to m, Z is Zero or a positive integer less than or equal 
to ((2m+1)-2w), R is H, alkyl, hydroxyalkyl, or 
CnH2n+1)-O.R. where m is a positive integer from 1 to 
10, Z is zero or a positive integer less than ((2m+1)-r), r is 
zero or a positive integer less than or equal to 2m+1, and R' 
is independently H, alkyl, hydroxyalkyl, or saccharide. 
Certain particular embodiments of the invention relate to 
sapphyrin multimers comprising sapphyrin derivatives that 
are water-soluble due to the presence of hydroxy substitu 
ents on the sapphyrin periphery. Representative water 
soluble sapphyrins are disclosed in parent application U.S. 
Ser. No. 07/964,607, incorporated herein by reference. 
Water-soluble sapphyrins are particularly desirable where 
one would like to exploit the various surprising properties of 
the sapphyrin macrocycle in connection with human or 
animal applications. The nature of the polyhydroxylation is 
not particularly critical to achieving water solubility of the 
sapphyrin multimer, so long as at least one, and preferably 
three or four hydroxyl groups per sapphyrin macrocycle are 
incorporated into the structure. The inventors have found 
that the introduction of at least one hydroxyl group per 
sapphyrin macrocycle will be sufficient to achieve some 
degree of water solubility. 
One means for introducing hydroxyl groups into the 
sapphyrin macrocycle structure is simply through the addi 
tion of hydroxyalkyl substituents to the basic sapphyrin 
macrocycle unit, wherein the added substituents include one 














exemplary polyhydroxylated sapphyrins will be those that 
are modified to include structures such as hydroxymethyl, 
hydroxyethyl, hydroxypropyl, hydroxybutyl, dihydroxy 
alkyl, trihydroxyalkyl, or the like, at one or more R positions 
of the basic sapphyrin structure shown above. 
An alternative means of achieving polyhydroxylation is 
through the addition of sugar moieties such as a saccharide, 
polysaccharide, saccharide derivative or aminosaccharide, 
to the sapphyrin macrocycle structure. In such cases, it has 
been found that the addition of a single saccharide molecule 
to a sapphyrin macrocycle will achieve a degree of water 
solubility. These structures are referred to broadly herein as 
simply sapphyrin-Sugar or Sapphyrin-saccharide com 
pounds, conjugates or derivatives. The nature of the sugar is 
not particular critical to the achievement of water solubility, 
and a non-exhaustive, exemplary list of useful sugars in this 
regard is set forth in Table 1. 
TABLE 1. 











Galactose Sialic Acid 
Talose Alginic Acid 
Ribulose Chitosan 





In still other embodiments, the present invention relates to 
sapphyrin multimers comprising sapphyrin-nucleobase con 
jugates. As used herein, the term "sapphyrin-nucleobase 
conjugate' is intended to refer broadly to any conjugate 
formed by the covalent conjugation of any sapphyrin mac 
rocycle to any nucleobase. Moreover, as used herein the 
term "nucleobase' is intended to refer broadly to any moiety 
that includes within its structure a purine or pyrimidine, a 
nucleic acid, nucleoside, nucleotide, or any derivative of any 
of these. Thus, the term nucleobase includes adenine, 
cytosine, guanine, thymidine, uridine, inosine, or the like, 
bases, nucleotides or nucleosides, as well as any base, 
nucleotide or nucleoside derivative based upon these or 
related structures. Particular examples of a useful nucleo 
base are any purine or pyrimidine-based molecule that will 
effect an anticellular, antiviral, antitumor or antienzymatic 
effect, regardless of the underlying mechanism, Exemplary 
nucleobases are shown in Table 2, including preferred 
conjugates such as purine or pyrimidine antimetabolites 































In still further embodiments, the nucleobase component 
of sapphyrin-nucleobase conjugates will include a protected 
nucleobase having attached substituents that protect the 
nucleobase from inappropriate or undesirable chemical reac 
tion. Examples include substituents such as 9-fluorenylm 
ethyl carbonyl, benzyloxycarbonyl, 4-methoxyphenacy 
loxycarbonyl, t-butyl oxycarbonyl, 
1-adamantyloxycarbonyl, benzoyl, N-triphenylmethyl, 
N-di-(4-methoxyphenyl)phenylmethyl, and the like. Sap 
phyrin-nucleobase conjugates were demonstrated in the par 
ent application Ser. No. 07/964,607 to effect the selective 
through-membrane transport of nucleoside monophosphates 
at, or near, neutral pH. It is contemplated that sapphyrin 
nucleobase conjugates will have a wide variety of applica 
tions, ranging from their use as agents for selectively deliv 
ering an associated, biologically active nucleobase to a 
particular body or even subcellular locale. For example, in 
the case of antimetabolite nucleobases, it is contemplated 
that the sapphyrin-nucleobase conjugates will act to deliver 
the antimetabolite to subcellular sites through the DNA 
binding activity of the sapphyrin portion of the conjugate. 
Perhaps more importantly, it is recognized that many, many 
nucleobase antimetabolites cannot be readily employed in 
therapy due to the fact that their charged nature inhibits their 
uptake by target cells, or otherwise inhibits or suppresses 
their unencumbered movement across biological mem 
branes. Typically, this shortcoming is due to the presence of 
charged structures such as phosphates, phosphonates, Sul 
fates or sulfonates on the nucleobase which, due to their 
charged nature, prevents or inhibits their crossing of a 
biological membrane. It is proposed that sapphyrin multi 
mers of the present invention can be employed as transport 
agents for carrying such nucleobases across membranes, 
(whether the nucleobase is directly conjugated to at least one 
of the sapphyrin macrocycles or simply complexed with it). 
It is contemplated that multimers of sapphyrin-nucleobase 
conjugates can be employed to carry hydrogen bonded poly 
or oligo-nucleotides into target cells through complementa 
rity with the sequence of bases "encoded” on the sapphyrin 
nucleobase polymer. One of the advantages of a sapphyrin 
multimer over a monomer is that a multimer will allow a 
more appropriate balance of charges between, for example, 












The foregoing general structure could be exemplified by 
the formula: 
wherein X is a sapphyrin macrocycle, N is a conjugated 
nucleobase structure, and Y is a hydrogen bonded poly- or 
oligonucleotide. 
Alternatively, it is contemplated that sapphyrin multimers 
of the present invention may serve as a carrier for polymers 
of nucleobases, wherein the nucleobase polymers are 
attached covalently to the Sapphyrin macrocycle, such as 
might be exemplified through the structural designation: 
wherein X is a sapphyrin macrocycle, and N is a selected 
oligomeric or polymeric nucleotide or other nucleobase, and 
Y is a hydrogen bonded poly- or oligonucleotide. Such a 
structure would be useful in a number of contexts, such as 
a specific carrier for complementary nucleotides such as 
antisense molecules. 
Due to the unique mode of DNA interaction, a sapphyrin 
polymeric molecule will possess an unrivaled ability to act 
as a general DNA binding platform. This has the distinct 
advantage that it can be modified so as to adjust both target 
cell specificity and degree of interaction with the DNA. For 
sapphyrin multimers, the basic site of interaction with the 
DNA involves the interior of the sapphyrin macrocycle, so 
that the exterior positions R'-R' can be substantially 
modified without significantly disrupting the DNA binding 
interaction. These exterior positions can be used to system 
atically adjust features such as solubility, membrane perme 
ability and cell selectivity. Furthermore, groups designed to 
modulate interaction with DNA can be attached to the 
exterior of the sapphyrin multimers, including alkylating 
functions (bronoacetamido groups, epoxides etc.) to pro 
vide covalent attachment to DNA or ene-diyne moieties to 
allow for double-stranded cleavage. 
A further and important advantage of the sapphyrin sys 
tem is that the simple DNA binding motif has been extended 
to several multimeric structures, in which multiple sapphy 
rins covalently linked together will be able to bind simul 
taneously and thus strengthen the entire interaction. This 
feature will allow a modular approach in which the appro 
priate number (2-10, 2-15, 2-20, 2-25, 2-30 or 2-40) of 
sapphyrin molecules is attached in a single molecule, per 
haps with different sapphyrin units containing sapphyrin 
derivatives with different groups attached that control such 
important properties as solubility, target cell specificity and 
DNA modification ability. 
To synthesize multitopic receptors, the inventors devel 
oped strategies to address the following objectives: (i) the 
independent development of molecular recognition strate 
gies for the complexation of two very different kinds of 
substrates (charged anionic and neutral nucleobase); (ii) 
their subsequent co-combination so as to provide receptors 
bearing both kinds of binding subunits; and (iii) various 
alternative methods of receptor oligomerization so as to 
provide oligomeric species bearing numerous combinations 
of multitopic receptors. 
Pursuing these strategies led to the development of the 
sapphyrin-based ditopic receptor systems disclosed in parent 
application Ser. No. 07/964,607, capable of recognizing both 
the anionic phosphate and the neutral portions of the nucle 
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otide derivatives, such as the purine or pyrimidine moieties. 
Molecules of this type are, indeed, capable of binding and 
transport of nucleotides and their derivatives. This theme 
was extended to the preparation of oligomeric, multitopic, 
receptors capable of recognizing multiple phosphate anions 
and nucleobase portions of nucleotide derivatives arranged 
in specific sequences. 
The ditopic receptor systems are ideal vehicles for the 
intracellular transport of nucleotides and their derivatives, 
including anti-viral agents. The multitopic receptors, like 
wise are contemplated to be of use in binding to oligonucle 
otides and specific sections of DNA or RNA and in trans 
porting such nucleic acid segments into cells. The phosphate 
and nucleic acid base ("nucleobase') recognition, through 
membrane transport and cell delivery properties of the 
present invention are thus applicable to the recognition and 
delivery of a large variety of monomeric and oligomeric 
species, including DNA, RNA and antisense constructs. 
The present invention therefore encompasses sapphyrin 
nucleotide oligomers and polymers. The oligomeric linkage 
in such molecules may take place at various places in the 
sapphyrin or sapphyrin-nucleobase monomers. 
The sapphyrin oligomers and polymers of the present 
invention include relatively low-number conjugates, such as 
dimers and trimers, and also larger oligomers or polymers. 
The oligomers will generally include between about 2 and 
about 8 residues, or even up to 20 residues, whereas the 
polymers may generally comprise up to about 100 residues, 
or even up to about 200 residues. 
The monomeric units employed in the synthesis of sap 
phyrin multimers may be known sapphyrin molecules, such 








herein by reference. Equally, any of the novel sapphyrin 
derivatives disclosed in parent application U.S. Ser. No. 
07/964,607 may be employed, in any combination, to create 
further novel sapphyrin dimers, trimers, oligomers or poly 
mers. Encompassed within the term "multimers' are those 
sapphyrin conjugates synthesized by the controlled addition 
of particular monomeric units and those produced by more 
uncontrolled polymerization methods. 
The inventors have additionally found that sapphyrin 
dimers act as effective receptors for dicarboxylate anions. 
Di- and tricarboxylates are critical components of numerous 
metabolic processes including, for instance, the citric acid 
and glyoxylate cycles. They also play an important role in 
the generation of high energy phosphate bonds and in the 
biosynthesis of important intermediates. In the present 
invention, two protonated sapphyrins (10 and 12, FIG. 1) 
serve as the key carboxylate-binding "building blocks' to 
chelate a dicarboxylate anion (20) while a flexible diami 
nopropane "spacer” (14) serves as the macrocycle-to-mac 
rocycle linking chain. This choice provides a system that 
rivals the best of the extant systems in terms of absolute 
binding efficacy in highly polar solvents (e.g., methanol) 
while displaying a very different kind of inherent substrate 
binding selectivity. 
Sapphyrin Multimers 
Specific examples of sapphyrin multimers include, but are 

















Sapphyrin multimers have been prepared by the conden 
sation of sapphyrin mono and bis acids with amino groups 
as spacer units. As di- and tri-amino spacers, ethylenedi 
amine, 1,3-diaminopropane, 1,3- and 1,4-phenylenedi 
amine, diaminonaphthalenes and anthracenes, for example, 
have been used in the synthetic approach. Sapphyrin trimers 
were built in a one-step reaction, in which 3 molar equiva 
lents of sapphyrin mono acid were combined with a 
trisamino component, e.g. tris(aminoethyl)amine, in very 
high yield. 
For the coupling reaction, a variety of different methods 
have been used. These include, for example, acid chloride, 
O-acylurea, mixed anhydride and N-acylimidazole, which 
were found to be particularly successful. The synthetic 
methodology employed was essentially the same as that 
developed to prepare sapphyrin-nucleobase conjugates (as 
disclosed in parent application U.S. Ser. No. 07/964,607). It 
is important to emphasize that the synthesis of both the 
sapphyrin-nucleobase conjugates and the sapphyrin oligo 
mers and polymers may be readily performed using a 
standard automated oligonucleotide synthesizer. 
The present inventors have prepared dimers and trimers of 
sapphyrins and have proven them to be very efficient rec 
ognition species for nucleotides, monophosphates, diphos 
phates and triphosphates. The formation of noncovalently 
bonded complexes between sapphyrin oligomers and a 
nucleotide allows the transport of nucleotide mono-, di- and 
triphosphates across cell membranes to occur at physiologi 
cal pH. This will likely be of direct use in the transport of 
antiviral triphosphates to mammalian cells, especially for 
the treatment of AIDS. 
Any of the novel sapphyrins disclosed in parent applica 
tion U.S. Ser. No. 07/964,607 may be employed, in any 
combination, in the synthesis of novel sapphyrin multimers. 
The synthetic approach developed is equally suitable to the 
use of one or more novel sapphyrin derivatives as starting 
materials as it is to the use of known sapphyrins. 
Sapphyrin polymers contemplated by the present inven 
tion include those compounds resulting from the polymer 
ization of monomeric units, by various types of processes 
other than those using a resin. For example, radical poly 
merization of olefin-substituted sapphyrin may be employed 
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to give a polyethylene type of polymer. Alternatively, poly 
condensation of Sapphyrin bis acid with sapphyrin diamine 
could be used to give a polyamide type of polymer, or 
polycondensation of Sapphyrin bis acid with sapphyrin bis 
alcohol may be employed resulting in a polyester type of 
20 
polymer. In all of these cases, sapphyrin-based polymers 
may be prepared both with and without covalently bonded 



















Two alternative methods for the preparation of 14 are 
shown in Schemes 2 and 3. 
SCHEME 2 
EDC, HOBt 6+ 13.5i SE > 
CONH HNOC CO2H 
15 
FEER-S 13 DMF, 3 days 14 
SCHEME 3 
1) 1,1'-CDIM, HOBt 












The synthesis of cyclic trimer 36 is accomplished as 
shown in Scheme 4, and Scheme 5, part 1 and 2. 
SCHEME 4 
1) 1,1'-CDIM, HOBt 
CHOH, HC 2) H2NCH2CH2NHR 







SCHEME 5, PART 2 







The synthesis of tethered sapphyrin tetramer 25 is 








The synthesis of cyclic dimer 19 is described in Example of the invention, and thus can be considered to constitute 
2, the structure is as follows. preferred modes for its practice. However, those of skill in 




The following examples are included to demonstrate the art should, in light of the present disclosure, appreciate 
preferred embodiments of the invention. It should be appre 
ciated by those of skill in the art that the techniques 65 
disclosed in the examples which follow represent techniques 
discovered by the inventors to function well in the practice without departing from the spirit and scope of the invention. 
that many changes can be made in the specific embodiments 





SYNTHESIS OF SAPPHYRIN DERIVATIVES 
HAVING ACARBOXY 7a, AN ESTER 7b, OR 5 
AN ACYL GROUP 7c, FOR USE AS 
PRECURSORS 
The synthesis of the precursor 3,8,1722-tetraethyl-12 
(carboxyethyl-2,7,13,18,23-pentamethylsapphyrin, struc- 10 
ture 7a, is a two-part procedure requiring the preparation of 
the ester 3,8,17,22-tetraethyl-12-(methoxycarbonylethyl)-2, 
7,13,18,23-pentamethylsapphyrin, structure 7b, and subse 
quent hydrolysis to the sapphyrin acid of general structure 
7a. Ester 7b was prepared in accord with the general 
optimized procedure for the production of substituted 
sapphyrins', incorporated herein by reference. 4,4'-Diethyl 
5,5'-diformyl-3,3'-dimethyl-2,2'-bipyrrole (272 mg, 1.0 
mmol) and 2,5-bis(5-carboxy-3-ethyl-4-methylpyrrol-2-yl 
methyl)-3-methoxycarbonylethyl-4-methylpyrrole (523 mg, 
1.0 mmol) were condensed to give this desired sapphyrin 
product in 75.4% yield (0.490 g). 
*H NMR (300 MHz, CDC1): 8–4.78 (1H,s.NH), -4.76 
(1H, s, NH), -4.32 (1H,s, NH), -4.13 (2H,s, NH), 2.35-243 25 
(12H,m, CHCH), 3.85 (2H, t, CH2CHCOCH), 3.99 
(3H,s, CH), 4.29 (6H, s, CH), 4.38 (3H,s, CH), 4.44 
(3H,s, CH), 4.67-4.74 (8H, m, CHCH), 5.22 (2H, t, C 
HCHCOCH), 11.82 (1H,s, meso-H), 11.85 (1H,smeso 
H), 11.88 (2H.S.meso-H). 'C NMR (75 MHz, CDC): 30 
8-12.7, 13.1, 15.9, 17.8, 17.9, 21.0, 23.0, 37.1, 52.1, 91.5, 
92.0, 98.3, 98.4, 126.9, 127.0, 129.5, 129.6, 130.2, 132.7, 
132.8, 134.7, 135.3, 135.5, 136.6, 136.7, 137.7, 139.1, 
141.5, 141.7, 173.3. HRMS: Calcd. for CHNO: 
643.3886. Found 643.3887. 35 
Sapphyrin acid 7a was prepared as follows: a ca. 1:1 v.v. 
mixture of trifluoroacetic acid and conc. hydrochloric acid 
(10 mL for 100 mg of starting sapphyrin 7b) was used to 
hydrolyze the ester 7b. The reaction was run at 50° C. for 2 
days after which time the desired sapphyrin acid product 7a 
was obtained as its bis HCl adduct. After drying in vacuo, 
this protonated product was purified by column chromatog 
raphy on silica gel (methanol 5% in dichloromethane, elu 
ent). The yield was ca. 95%. 
H NMR (300 MHz, CDC1): 8-5.84 (2H, bs, NH), 
-5.35 (3H, bs, NH), 2.20 (12H, t, CHCH), 3.23 (2H, t, 
CHCHCO2H), 4.03 (3H,s, CH), 4.15 (6H,s, CH), 4.23 
(3H,s, CH), 4.41 (3H,s, CH), 4.65 (4H, q, CHCH), 4.74 
(4H, q, CHCH), 4.79 (2H, m, CHCHCO2H), 11.42 50 
(2H,s,meso-H), 11.55 (1H,s,meso-H), 11.58 (1H,s,meso-H). 
°C NMR (75 MHz, CDC1,): 812.7, 12.9, 14.3, 15.9, 17.7, 
17.9, 20.6, 20.9, 22.8, 36.5, 36.7, 61.9, 91.6, 98.1, 120.7, 
120.9, 125.4, 125.4, 127.3, 129.1, 129.2, 130.0, 132.7, 
132.8, 134.8, 1349, 135.2, 135.4, 135.6, 135.7, 136.1, 55 
136.8, 136.9, 137.0, 137.7, 139.31, 1414, 1418, 141.8, 
1744. FAB MS, mile (rel intensity): 631 (48, MH"), 630 
(100, MH), 629 (52, M); HRMS: Calcd. for 
CHNO: 629.3730. Found 630,3798 (MH); for 
CHNO (MH: Calcd. 630.3808. 60 
The sapphyrin acid 7a, as prepared above (63 mg, 0.1 
mmol), was dissolved in 10 mL of dry dichloromethane 
under argon. Oxalyl chloride (0.2 mL) was added followed 
by 0.03 mL of DMF. The reaction mixture was stirred at 
room temperature for 3 hours under argon and then evapo- 65 
rated to dryness in vacuo to give the corresponding sapphy 





PREPARATION OF LINEAR AND CYCLIC 
SAPPHYRIN DIMERS 
The present example describes the preparation of linear 
and cyclic sapphyrin dimers. Sapphyrin monoacid 7a (126 
mg, 0.2 mmol) was converted to acid chloride 7c as 
described hereinabove. A solution of the acid chloride in dry 
dichloromethane (20 mL) was slowly added to a solution of 
0.1 mmol of an aromatic bis(amino) 
STRUCTURES: 
1a. R = R = CHCH 
7a. R = CHCHCOCOH; R = CH, 
7b, R = CHCHCOCH.; R = CH 
7c. R = CHCH,COCl; R = CH, 
compound in dry dichloromethane (20 mL), which con 
tained 5 mg 4-dimethylaminopyridine and 0.3 mL of dry 
pyridine. The reaction mixture was stirred 48 hours at room 
temperature, then washed with water, the organic phase was 
dried with magnesium sulfate and evaporated. The product 
was isolated by column chromatography on silica gel in 
dichloromethane with 2-10% of methanol as the eluent. 
Reaction with 1,8-diaminonapthalene (0.1 mmol, 15.8 mg) 
gave 80 mg (57.89%) of product 21. 
FABMS mile (rel. intensity) 1382 (67, MH), 1381 (56, 
M"). HRMS Calcd. for CHNO: 1380.80916. 
Found 1380.8093. Reaction with m-phenylenediamine (0.1 
mmol, 10.8 mg) gave 69 mg (51.80%) of product 22. FAB 
MS m/e (rel. intensity) (78, MH)), 1332 (65, MI). 
HRMS Calcd. for CHNO: 1330.79352. Found 1330. 
79349. 
Preparation of 1,3-bis(12-aminocarbonylethyl-(3,8,1722 
tetraethyl-2,7,13,18,23-pentamethylsapphyrin)propane 23: 
Method A. (via DeC coupling) 
Reaction of sapphyrin monocarboxylic acid 7a with 1,3- 
diaminopropane was carried out using DCC as the coupling 
reagent. Sapphyrin acid 7a (126 mg, 0.2 mmol) was dis 
solved in dry dichloromethane under argon. The resulting 
solution was then cooled by ice to 0°C. Dicyclohexylcar 
bodiimide (0.25 g) was added along with 5 mg of hydroxy 
benzotriazole. The resulting reaction mixture was stirred at 
0 C. for 30 minutes and then 1,3-diaminopropane (7.4 mg, 
0.1 mmol) was added. Stirring was then continued for 30 
minutes at 0° C. and then for 48 hours at room temperature. 
Following this, acetic acid (0.2 mL) was added and the 
reaction mixture stirred for 1 hour before dicyclohexylurea 
was filtered off. The product was purified via column 
chromatography using silica gel as the solid support and a 
gradient of 2-10% methanol in dichloromethane as the 
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eluent. The yield of compound 23 (free-base form) was 96 
mg (74.1%). 
Vis (CHCl containing 3%. CFCOH): (nm) 449.0, 
623.0, 681.0 FAB MS m/e (rel. intensity): 1298 (67, M 
H)), 1299 (60, MH"). HRMS: Calcd. for C8HoN2O, 
M H: 1297.8170, found 1297.8195. 
Method B. (via acid chloride) 
The sapphyrin acid 7a (63 mg, 0.1 mmol) was converted 
to its corresponding acid chloride (7c) via the method 
described hereinabove. The sapphyrin acid chloride was 
then redissolved in dry dichloromethane (20 mL) and slowly 
added to a solution of 1,3-diaminopropane in dry dichlo 
romethane that contained 5 mg of 4-dimethylaminopyridine 
and 0.3 mL of dry pyridine. The resulting reaction mixture 
was stirred 48 hours at room temperature and washed with 
water. The remaining organic phase was dried over magne 
sium sulfate and evaporated to dryness. Product 23 (77% 
yield) was then isolated as described in Method A. 
In general, the best yields (2.70%) were obtained when 
the sapphyrin acid chloride 7c was used; however, the 
corresponding acylimidazole, mixed anhydrides, and acti 
wated esters could also be used. 
Synthesis of Mono- and Bis-saccharide-Substituted Sapphy 
S. 
In general, saccharide-substituted sapphyrins were pre 
pared by the reaction of an activated bis(sapphyrin) mono 
or bis-acid and a polyhydroxy-amino component. 
The synthesis of bis(sapphyrin) bis(acid) 35 is described 
in Example 3. This dimer may be further activated (via 
conversion to its acid chloride, a carbodiimide derivative, an 
NHS ester, or mixed anhydride) and reacted with an amino 
saccharide derivative (or a protected form thereof) to give 
the corresponding sapphyrin glycosamides. 
Bis(sapphyrin) monoacid 15 (Example 3) (0.1 mmol) was 
dissolved in 5 mL of dry DMF. Then, 1,1'-carbonyldiimi 
dazole was added (0.2 mmol) and the reaction mixture 
stirred at room temperature for 2 hours. A solution of 
D-glucosamine.HCl (0.2 mmol) in 3 mL of water containing 
0.3 mL of pyridine was then slowly added. The resulting 
reaction mixture was stirred for 4 days before being worked 
up in accord with the following procedure: Sodium bicar 
bonate (5 mL of a saturated aqueous solution) was first 
added. Then after 5 min, the resulting precipitated product 
(15c) was filtered off, washed with cold water (3 mL) and 
dried. Yield of product 15c is 64.5%. (The structure of 15c 
is not shown, however, 15c is structure 15 where the 
carboxyl group is replaced with CO-NH-D-glucosamine) 
Characterization data: FAB HRMS: Calcd for CHNO 
(M+H3): 1502.87562; found: 1502.88245. UV-Vis (, 
HO, pH 7.0): 420444 623675. 
Preparation of Bis(Sapphyrin) Gluconamides: In general, 
the activated bis(sapphyrin) monoacid (15) described in 
Example 3 was reacted with 1-amino-1-deoxy-D-sorbitol 
(or, in general, any D-glucanine in DMF-water (or aqueous 
buffer, pH 7.5–9) mixtures to give the sapphyrin glucona 
mides. Here, activation was effected using carbodiimide 
derivatives such as EDC or 1,3-diisopropylcarbodiimide or 
via the use of mixed anhyrides. 
Bis(sapphyrin)-D-glucanide 15b. Bis(sapphyrin) 
monoacid 15 (0.1 mmol) was dissolved in dry DMF (5 mL) 
and cooled to 0° C. EDC (96 mg, 5 mmol) was then added 
together with 5 mg of 1-hydroxybenzotriazol. The resulting 
solution was stirred with external ice bath cooling for 1 hour. 
At this juncture, the chosen D-glucamine in this case, 
1-amino-1-deoxy-D-glucitol; alternative name: 1-amino-1- 
deoxysorbitol) (108.7 mg, 6 mmol) in water (3 mL) and 













lowing this addition, the reaction mixture was stirred with 
cooling for 1 additional hour before being stirred for 7 more 
days at rit. Work up consisted of adding 3 mL of saturated 
solution of sodium bicarbonate and then filtering off the 
resulting precipitate 5 minutes later. The resulting product 
15b was washed with cool water (3 mL) and dried. Yield of 
15b 110.6 mg (73.3%). (The structure of 15b is not shown, 
however, 15b is structure 15 where the carboxyl group is 
replaced with CO-NH-D-glucamine. Characterization 
data: FAB MS: Calcd for CHNOs (M-Ha"): 
1505.899159; found 1505.900165. UV-Vis (, HO, pH 
6, bis(tris)buffer): 417 444 623 675. 
A cyclic sapphyrin dimer 19 may be prepared by reacting 
6 and 16 or, alternatively, reacting 32 with EDC, HOBt and 
DMF for about 3 days. 
EXAMPLE 3 
PREPARATION OF TETHERED, LINEAR AND 
CYCLIC SAPPHYRIN TRIMERS 
Tethered, linear and cyclic sapphyrin trimers were syn 
thesized using similar coupling procedures as described 
above for the sapphyrin dimers. Thus, sapphyrin monoacid 
7a (189 mg, 0.3 mmol) was coupled (DCC method, 0.75 g) 
with tris(2-aminoethyl)amine (14.6 mg, 0.1 mmol) giving 
160 mg (80.73%) of tethered sapphyrin trimer 24. FAB MS 
m/e (rel. intensity) 1983 (36, MH"), 1982 (32, (MI"). 
HRMS Calcd. for CHNO: 1980.240296. Found 
1980.240289. 
A further linear sapphyrin trimer 14 was prepared as 
follows. Proton and 'C NMR spectra were recorded on 
General Electric QE-300 spectrometer. Fast atom bombard 
ment mass spectra (FABMS) were obtained using a Finni 
gan-MAT TSQ-70 instrument and 3-nitrobenzyl alcohol 
matrix. All solvents and reagents were of reagent grade 
quality, purchased commercially, and used without further 
purification. Merck type 60 (230–400 mesh) silica gel was 
used for column chromatography. Thin layer chromatogra 
phy (TLC) was performed on silica gel plates purchased 
from Whatman, Inc. 
3,12,13.22-Tetraethyl-8,17-di (carboxyethyl)-2,7,18,23 
tetramethylsapphyrin 6 (Sessler et al., JACS, 112:2810, 
1990) and 3,8,17,22-Tetraethyl-12-(carboxyethyl)-2,7,13, 
18,23-pentamethylsapphyrin 7a (reference 12 and Example 
1) were prepared as described. t-Butoxycarbonylaminoethy 
lamine was prepared according Tarbel et al. (PNAS, 69:730, 
1972). 
3,8,17,22-Tetraethyl-12-(aminoethyl)-aminocarbonyl 
ethyl)-2,7,13,18,23-pentamethyl-sapphyrin 13. Sapphyrin 
acid 7a (252 mg, 0.4 mmol) was dissolved in 10 mL of dry 
DMF 1,1'-Carbonyldiimidazole (1,1'-CDIM) (130 mg, 0.8 
mmol) and 1-hydroxybenzotriazole hydrate (HOBt) (10 mg) 
were added and the solution was stirred for 2 h at room 
temperature. A solution of t-butoxycarbonylaminoethy 
lamine (128 mg, 0.8 mmol) in 2 ml of dry DMF was added 
all at once. The resulting solution was stirred for20 h after 
which solvent was evaporated in vacuo. The protected 
aminosapphyrin was purified by column chromatography on 
silica gel using methanol, 2-10% in dichloromethane as the 
eluent. To deprotect, it was dissolved in a mixture of dry 
dichloromethane (5 mL) and dry trifluoroacetic acid (5 mL) 
and stirred for 8 h. Solvent was evaporated in vacuo. The 
yield of 13 obtained this way was 208 mg (ca. 78%). 
H NMR (free base) (300 MHz, CDCl): 8=-2.76 (3H, 
bs.NH), 1.93 (12H, m, CHCH), 2.69 (2H,bs CH), 3.02 
(2H,bs,CH), 4.27 (15H,m, CH), 4.39 (10H,m, CH2), 4.61 
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(2H,bs,NH), 10.19 (1H,s, meso-H), 10.58 (1Hs, meso-H), 
10.62 (1Hs, meso-H), 10.67 (1H,s, meso-H). CNMR (free 
base) (75 MHz, CDC, with 10% CdOD): 8=1205, 12.11, 
12.24, 12.43, 15.88, 16.03, 17.54, 20.20, 20.26, 20.45, 
20.51, 23.17, 38.91, 39.89, 41.14, 89.32, 89.72, 89.86, 
94.41, 94.45, 95.38, 126.82, 132.15, 132.60, 132.86, 133.28, 
133.56, 133.90, 134,03, 136.91, 137.27, 138.04, 139.92, 
140.30, 142.34, 172.82. FAB MS, mile (re. intensity): 671 
(57, M), 670 (17, M-H"). HRMS Calcd. for 
CHNO: 670,4233. Found 670.4218. 
Synthesis of the bis(sapphyrin) monoacid 15. 
Aminosapphyrin 13 and sapphyrin bisacid 6 were mixed 
in equimolar amounts. ADMF solution of 1.3 equivalents of 
EDC and 10 mg of HOBt were added at 0°C. The reaction 
mixture was stirred at that temperature for 30 min. and then 
allowed to warm to room temperature. Stirring was contin 
ued for 3-5 days (TLC control). Solvent was evaporated in 
vacuo. Product 15 was isolated in 45% yield by column 
chromatography on silica gel using methanol, 212% in 
dichloromethane, as the eluent. FABMS mile (re. intensity): 
1344 (18, M+2H), 1343 (39, M+H"), 1342 (36, M), 
HRMS Calcd. for CHNO: 1341.8068 Found 
1341.6410. 
Synthesis of sapphyrin trimer 14: 
Sapphyrin trimer 14 was obtained in three different ways 
by means of coupling reactions in DMF, Aminosapphyrins 
and sapphyrin mono- and bisacids were mixed in the fol 
lowing ratios: 1 (13)+0.5 (6); or 1 (15)+1 (13); or 1 (7a)+0.5 
(16) in 0.1 mmol amounts. DMF solution of 1.3 equivalents 
of 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydro 
chloride (EDC) and 10 mg of 1-Hydroxybenzotriazole 
hydrate (HOBt) were added at 0°C. Reaction mixtures were 
stirred at that temperature for 30 min. and then allowed to 
warm to room temperature. Stirring was continued for 3-5 
days (TLC control). Solvent was evaporated in vacuo. 
Product 14 was isolated in 400% yield by column chroma 
tography on silica gel using methanol, 2-15% in dichlo 
romethane, as the eluent. 
H NMR (TFA salt) (500 MHz, CDC with 10% 
CDOD): 81.9 (42H, m), 2.6 (8H, m), 3.1 (8H,bs), 4.2 
(32H,m), 4.6 (42H,m) 1, 11.7 (12H, bs, meso-H). CNMR 
(TFA salt) (161 MHz, CDC1, with 10% CDOD): 8-1242, 
15.39, 17.28, 1798, 20.45, 22.90, 23.40, 29.53, 37.92, 
38.45, 90.76 (m), 97.56 (m). 110.33, 112.67, 126.96 (m), 
127.30 (m), 128.63 (m), 129.30 (m), 131.88 (m), 132.10 
(m), 134.52 (m), 135.50 (m), 136.70 (m), 137.07 (m), 
138.27, (m), 139.93 (m), 141.62 (m), 142.36 (m), 154.36 
(m), 172.51 (m). All signals have fine structure. FAB MS, 
m/e (rel. intensity): 1998 (63, M+2H)), 1997 (77, M=H 
“), 1996 (93, M), 1995 (76, M-HI), 1994 (51, M-2H), 
1993 (29, M-3H]), 1992 (20, M-4H"). HRMS Calcd. 
for C2HNO: 1996.2353. Found 1996. 2366 (M). 
3,12,13,22-Tetraethyl-8,17-di(aminoethyl)aminocarbonyl 
ethyl)-2,7,18,23-tetramethylsapphyrin 16. The procedure 
described for the preparation of 13 was followed. Bisami 
nosapphyrin 16 was obtained in 72% yield. "H NMR (free 
base) (300 MHz, CDC1): 8=5.94 (1H,s,NH), -5.54 (1H,s, 
NH), -5.48 (1H,s,NH), 1.59 (6H,m, CHCH), 1.96 (6H,t,C 
HCH), 2.96 (4H,m, CH), 3.17 (4H,m, CH), 3.96 (6H,s, 
CH), 4.01 (6H,s,CH), 4.29 (4H,q, CHCH), 4.56 (4H,q, C 
HCH), 4.77 (6H.m.,CHCH), 8.17 (2H,t,NHCO), 9-18 
(4H,bs,NH), 11.54 (2H,s, meso-H), 11.59 (2H,s, meso-H). 
CNMR (free base) (75 MHz, CDC1, with 10% CDOD): 
8=12.64, 15.40, 17.38, 18.31, 20.48, 20.54, 23.04, 36.82, 
38.34, 39.14, 92.04, 98.74, 128.43, 129.01, 129.85, 132.53, 













FABMS, m/e (rel. intensity): 774 (30, M--2H)"), 773 (76, 
M+H), 772 (100M"), 771 (29, M-H"). HRMS Calcd. 
for CHNO: 772.5026. Found 772.5014. 
A further sapphyrin cyclic trimer 36 was synthesized as 
follows. 
3,12,13,22-Tetraethyl-8-(methoxycarbonylethyl)-17-car 
boxyethyl-2,7,18,23-tetramethyl-sapphyrin (30): Sapphyrin 
bisacid 6 (190 mg, 0.25 mmol) was dissolved in 50 ml of 
acetone, methanol (2 mL) and concentrated aqueous solu 
tion of HCl (1 mL) were added. The mixture was stirred for 
2-6 hrs (formation of products was monitored by TLC). A 
saturated solution of sodium bicarbonate (3 mL) was added, 
acetone and methanol were evaporated and the residue 
extracted with 10% methanoldichloromethane solution. The 
organic layer was separated, dried with anhydrous sodium 
carbonate and evaporated. Monoprotected sapphyrin 30 was 
isolated by column chromatography on silica gel using 
methanol, 2-10% in dichloromethane, as the eluent. 
H NMR (TFA salt) (300 MHz, CDC1): 8–5.11 (1Hs, 
NH), 5.05 (1H,s,NH), -4.74 (1H,s,NH), 4.58 (1Hs,NH), 
4.52 (1H,s,NH), 1.01 (2H,m), 1.19 (2H,m), 1.42 (2H,m), 2.1 
(8H,bs), 2.24 (3H,s), 3.13 (2H, bs ), 3.59 (2H,bs), 3.68 
(2H,bs), 4.04 (2H,bs), 4.13 (4H,bs), 4.26 (2H,bs), 4.59 
(8H,m), 5.05 (2H,bs), 11.48 (1H,s, meso-H), 11.63 (3H,m, 
meso-H). CNMR (TFA salt) (75 MHZ, CDC with 10% 
CDOD): 8=12.63, 12.76, 13.86, 15.42, 17.33, 18.09, 20.65, 
22.73, 36.69, 51.81, 90.99, 91.46, 98.34, 98.39, 127.58, 
128.57, 129.22, 129.34, 129.47, 129.99, 130.78, 132.35, 
132.42, 135.08, 135.15, 135.47, 135.99, 137.34, 137.63, 
138.04, 138.14, 141.76, 141.86, 144.19, 143.46, 173.27. 
FAB MS m/e (rel. intensity): 704 (100, M+2H), 703 (36, 
M+H"), 702 (77, M). HRMS Calcd. for CHNO: 
702.4019. Found 7023997. 
3,12,13,22-Tetraethyl-8-(t-butoxycarbonylaminoethy 
l)aminocarbonylethyl-17-(methoxy-carbonylethyl)-2,7,18, 
23-tetramethylsapphyrin 31: The general procedure for 
preparation of aminosapphyrins was followed, excluding the 
deprotection step. The yield of 31 obtained was 73%. H 
NMR (HCl salt) (300 MHz, CDC1): 8=1.16 (9H,s), 2.25 
(12H,m), 2.77 (2H,bs), 3.01 (2H,bs), 3.27 (2H,m), 3.63 
(2H,m), 3.79 (3H,s), 4.08 (3H,s), 4.09 (3H,s), 4.18 (3H,s), 
4.26 (3H,s), 4.52 (4H,m), 4.70 (4H,m), 5.02 (4H,m), 5.86 
(2H,m), 11.51 (4H,m). C NMR (HCl salt) (300 MHz, 
CDC1, with 10% CDOD): 8=12.71, 12.85, 12.90, 15.95, 
16.18, 17.64, 17.72, 18.36, 18.41, 20.71, 22.69, 23.36, 
27.90, 28.12, 36.82, 38.84, 39.34, 51.97, 78.88, 91.26, 
91.91, 97.45,97.57, 115.56, 115.81, 121.17, 123.03, 127.05, 
128.49, 128.68, 129.31, 129.37, 129.54, 129.59, 132.03, 
132.44, 134.64, 135.06, 135.20, 135.26, 138.11, 138.40, 
138.48, 138.82, 143.28, 143.34, 143.69, 143.93, 144.16, 
172.94, 173.17. FAB MS m/e (re. intensity): 846 (26, 
M-2H)"), 845 (66, M+H"), 844 (98, M"), 843 (26, 





Aminosapphyrin 33 was obtained in 82% yield from 31 
by following general deprotection procedure. H NMR 
(FREE BASE) (300 MHz, CDC1, with 10% CDOD): 
8=1.97 (2H,m), 2.10 (6H,m), 2.25 (6H,m), 3.42 (2H,m), 
3.58 (2H,m), 3.67 (3H,s), 4.16 (6H,bs), 4.24 (3H,s), 4.27 
(3H,s), 4.56 (4H,m), 4.76 94H,m), 5.03 (4H,m), 11.63 
(1H,s,meso-H), 11.65 (1H,s,meso-H), 11.72 (1H,s, meso-H), 
11.78 (1H,smeso-H). C NMR (free base) (300 MHz, 
CDCl with 10% CDOD): 8-12.65, 12.85, 15.84, 1747, 
17.57, 18.25, 18.31, 20.58, 20.72, 22.72, 23.39, 36.29, 
5,587.478 
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36.79, 38.20, 38.66, 51.92, 90.97, 92.36, 97.48, 98.02, 
122.62, 126.95, 128.46, 129.01, 129.43, 129.71, 132.22, 
132.31, 132.42, 134.83, 135.17, 135.32, 137.92, 138.43, 
138.56, 139.33, 142.69, 143.58, 144.51, 173.24, 173.69. 
FAB MS m/e (rel. intensity): 746 (42, M--2H), 745 (98, 5 
M+H"), 744 (95, M"), 743 (32, M-H"). HRMS Calcd. 
for CHNO: 744. 4601. Found 744.4594. 
Synthesis of sapphyrin 34. 
Aminosapphyrin 33 and sapphyrin bisacid 6 were mixed 
in equimolar amounts. DMF solution of 1.3 equivalents of 10 
EDC and 10 mg of HOBt were added at 0°C. The reaction 
mixture was stirred at that temperature for 30 min. and then 
allowed to warm to room temperature. Stirring was contin 
ued for 3-5 days (TLC control). Solvent was evaporated in 
vacuo. Product 23 was isolated in 57% yield by column 15 
chromatography on silica gel using methanol, 2-12% in 
dichloromethane, as the eluent. FABSMS m/e (tel. inten 
sity): 1416 (32, M+3H]"), 1415 (65, M--2H)"), 1414 (99, 
M+H"), 1413 (98, M"), 1412 (50, M-H"). HRMS Calcd. 
for CHNO: 1413. 8280. Found 1413.8299. 
Synthesis of sapphyrin dimeric hisacid 35. 
Compound 34 was dissolved in the mixture of TFA:H- 
CL=1:1 and the resulted solution was subjected to reflux 
at 70° C. for 5 h. Solvents were evaporated in vacuo. 
Compound 35 was obtained in 93% yield and used without 25 
further purification. FABSMS m/e (rel. intensity): 1401 (77, 
(M+3H]"), 1400 (100, M+2H), 1399 (86, M+H"), 1398 
(42, M). HRMS Calcd. for CHNO (M+2H): 
1400.8202. Found 1400. 81.99. 
Synthesis of sapphyrin cyclic trimer 36. 
Sapphyrin dimeric bisacid 35 and bisaminosapphyrin 16 
were mixed in the equimolar amounts. DMF solution of 2.6 
equivalents of EDC and 10 mg of HOBt were added at 0°C. 
Reaction mixture was stirred at that temperature for 30 min. 
and then allowed to room temperature. Stirring was contin- 35 
ued for 3-5 days (TLC control), added. Solvent was evapo 
rated in vacuo. Product 36 was isolated in 28% yield by 
column chromatography on silica gel using the mixture of 
methanol, (2-20%), TFA (1%), in dichloromethane, as the 
eluent. FAB MS m/e (rel. intensity): 2143 (46, M+2H), 
2142 (64, M-I-HI), 2141 (98, M), 2140 (68, M-H)), 
2139 (46, M-2H)"). HRMS Calcd for C2HNO; 
2141.3329. Found 2141.3349. 
20 
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EXAMPLE 4 45 
SYNTHESIS OF A TETHERED SAPPHYRIN 
TETRAMER 
The present example provides for the synthesis of a 
tethered sapphyrin tetramer 25. 
Preparation of sapphyrin 25: 
Method A. (via diisopropylcarbodiimide coupling) 
A reaction of sapphyrin monocarboxylic acid 7a with 
aliphatic (amino), compounds (n=14) was carried with 
diisopropylcarbodiimide as a coupling reagent. Sapphyrin 
acid 7a (252 mg, 0.4 mmol) was dissolved in dry dichlo 
romethane under argon. The resulting solution was then 
cooled by ice to 0°C. 1,3-Diisopropylcarbodiimide (0.126 g. 
1 mmol) was added with 5 mg of 1-hydroxy-benzotriazole. 
The reaction mixture was stirred at 0°C. for 30 minutes and 
then tetrakis(2 aminoethyl)ethylenediamine (23.2 mg, 0.1 
mmol) was added. The reaction mixture was stirred for 30 
min. at 0° C. and 48 hours at room temperature. Acetic acid 
(0.2 mL) was added and the mixture stirred 1 hour. The 
product was then isolated by column chromatography on 






nol as the eluent. Yield of pure compound 25 is 168 mg 
(62.7%). 
FAB MS m/e (rel. intensity) 2679 (67, MH"), 2680 (60, 
MH"). HRMS Calcd. for CHNO (MH)": 
2679.70284. Found 2679.77100. H NMR (300 MHz, 
CDCl with 5% CDOD): 8=1.74 (24H.m, CHCH), 1.85 
(24H.m, CHCH), 2.61 (8H,m, CONHCH), 3.01 (12H, m, 
CONHCHCHN, NCHCHN), 3.40 (8H, t, CH,C 
H,CONH), 3.58 (24H.s,CH), 3.67 (12H.S.CH), 3.83 (18H, 
s,CH), 3.90 (6H.S.CH), 4.06 (16H,q, CHCH), 4.19 (16H, 
q,CHCH.), 4.30 (8H, t,CHCHCONH), 9.85 (4h, S.me 
thine), 10.05 (4H,s, methine), 10.24 (4H.s...methine), 10.32 
(4H,s, methine). Vis 25 (free base), CHCL): : 428.0, 
449.0, 620.0, 642.0, 667.0. Vis 25 (CHCl with 3% TFA): 
: 448.0, 623.0, 681.0. 
Method B. (via acid chloride) 
The sapphyrin monoacid 3,8,17,22-tetraethyl-12-(car 
boxyethyl-2,7,13,18,23-pentamethylsapphyrin 7a (63 mg, 
0.1 mmol) was converted to its corresponding acid chloride 
via a standard procedure: The sapphyrin acid was dissolved 
in 25 mL of dry dichloromethane under argon. Oxalylchlo 
ride (0.2 mL) was then added, followed by 0.03 mL of DMF. 
The reaction mixture was stirred at room temperature for 3 
hunder argon and then evaporated in vacuo. The sapphyrin 
acid chloride so obtained was redissolved in dry dichlo 
romethane (20 mL) and slowly added to a solution of the 
tetraamine; tetrakis (2-aminoethyl)-ethylenediamine (5.8 
mg, 0.025 mmol), which contained 5 mg 4-dimethylami 
nopyridine and 0.3 mL of dry pyridine. 
The resulting reaction mixture was stirred 48 hours at 
room temperature, then washed with water. The organic 
phase was dried with magnesium sulfate and evaporated. 
The product was isolated by column chromatography on 
silica gel using dichloromethane containing 2-10% of 
methanol and 1-3% TFA as the eluent. Product 25 was 
obtained in 56.9% yield. 
EXAMPLE 5 
PREPARATION OF SAPPHYRIN POLYMERS 
For the preparation of polymers, sapphyrins with ethylene 
units could be used, as prepared by the elimination of 
acetoxy derivative, as well as sapphyrin bis acid, sapphyrin 
diamino- or dihydroxyderivatives. Sapphyrins bearing 
covalently attached nucleobases could also be used for the 
polymerization reactions. 
Radical polymerization may be catalyzed by dibenzoylp 
eroxide, or bisazaisobutyronitrilin inert solvent at tempera 
ture 120°-200° C. 
Polycondensation reaction: 3,12,13,22-Tetraethyl-8, 17 
bis(carboxyethyl-2,7,18,23-tetramethylsapphyrin (1 mmol) 
and 1,1'-carbonyldiimidazole (1.1 mmol) were mixed in 
diphenylether for 1 hour, then 3,12,13,22-tetraethyl-8, 17 
diaminoethyl-2,7,18,23-tetramethylsapphyrin (1 mmol) was 
added and the reaction was heated at 190°-250° C. for 2 
hours. After cooling, dichloromethane was added. Polymeric 
sapphyrin structure 26A (where X=NH) was filtered off, and 
washed with water (50 mL) and methanol (50 mL). 
Polymeric sapphyrin was obtained also by using sulfolan, 
hexamethylphosphortriamide as a solvent. The reaction 
could be also carried out without solvent. 
The same procedure was followed using the sapphyrin 
dialcohol as a starting compound for the preparation of 
sapphyrin diacid structure 26B (where X=O). 
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To synthesize structure 27, it is contemplated that one 
would employ standard phosphoramidate chemistry. 
The molecular weight (and, therefore, t) of sapphyrin 
polymers may be estimated by use of electrospray mass 
spectrometry which is applicable for molecular weights up 
to about 12,000. This determination may also be made using 
SEPHADEX(8) gel filtration (Sigma, St. Louis, Mo.), for 
example. 
EXAMPLE 6 
STEPWISE SYNTHESIS OF MULTIMERIC 
SAPPHYRIN-OLIGONUCLEOTIDE 
CONJUGATES 
The present example provides synthetic procedures in 
which a sapphyrin multimer is inserted directly into a 
nucleic acid synthesis scheme, preferably on a solid support. 
Sapphyrin macrocycles were not known to be stable under 
the basic conditions employed in the synthesis of oligo 
nucleotides. It was possible that the meso positions of 
sapphyrin would be unstable. Therefore, the stepwise syn 
thesis of sapphyrin oligonucleotide conjugates presented 
herein was a surprising and unexpected result. The synthesis 
of Sapphyrin-nucleobase conjugates is described in U.S. Ser. 
No. 07/964,607 and PCT/US93/09994, incorporated by ref 
erence herein. 
It is contemplated that the stepwise synthesis provided 
herein may be performed manually or may be automated, 
and may be in a solution-phase or on a solid support. Solid 
Support synthesis may be accomplished using an automated 
or a manual nucleic acid synthesizer. Common solid sup 
ports are CPG (control pore glass) and CPS (control pore 
silica). Other possible solid supports include polystyrene, 
polyamide/Kieselguhr, and cellulose paper. A preferred 
embodiment of this method is automated synthesis on a solid 
Support. Attachment of a sapphyrin multimer to an oligo 
nucleotide during stepwise synthesis obviates the need for a 
postmodification protocol and a second purification of the 
product. This results in an improved yield and greatly 
facilitates scale-up. 
A sapphyrin multimer may be inserted into the synthesis 
scheme of an oligonucleotide in a variety of ways. Possible 
linkages include amide, phosphate, thioether, amino, and 
ether linkages. An amide linkage represents the reaction of 
an activated carboxylic acid derivative of a multimer and an 
amino linker attached to an oligonucleotide. Activation may 
be achieved in solution phase or on a solid support using 
DCC and NHS, EDC, or activated esters of NHS, nitrophe 
nyl, pentachlorophenyl, acid anhydride, or sulfonyl chloride. 
In addition, for the solid support reaction, activation may be 
in the form of an acid chloride. A phosphate linkage repre 
sents the reaction of an activated phosphate derivative of a 
multimer and the 5’ hydroxyl group on an oligonucleotide. 
The activated phosphate may be a phosphoramidite, an 
H-phosphonate, a triester, or a diester. 
Sapphyrin-oligonucleotide conjugates have been made 
using a direct coupling amide linkage method or by incor 
poration during oligonucleotide synthesis forming a 5" link 
age via the H-phosphonate method as follows. 
Direct coupling method (amide linkage): 
Sapphyrinoligonucleotide conjugates with an amide link 
age were formed on a solid support. Specifically, sapphyrin 
monoacid 1a (6.8 mg, 0.011 mmol, 50 eq) was dissolved in 
2 mL of methylene chloride in a 4 mL glass vial with a small 
stir bar followed by cooling to 0° C. with an ice bath. 
Dicyclohexylcarbodiimide (4.5 mg, 0.022 mmol, 100 eq), 
dimethylaminopyridine (0.001 mg, catalytic amount), and 














added to the solution which was then stirred for 30 min. 
Protected amino- derivatized oligonucleotide attached to 
CPG solid support (2.5 mg, 0.108 umol, 1 eq) was added to 
the solution which was stirred overnight at room tempera 
ture. The solution was filtered and the conjugate attached to 
the CPG was washed once with methylene chloride and 
twice with methanol. The green solids were then suspended 
in conc. ammonium hydroxide for 4 hat room temperature 
after which the green solution was filtered and evaporated to 
afford the crude sapphyrinoligonucleotide conjugate. The 
conjugate could be purified by fplc on a C column using 
acetonitrile/100 mM triethylammonium acetate, pH 7.0. 
The coupling step in this case was done on a solid support 
although it may be done in solution. This procedure attaches 
sapphyrin to the 5' end of the oligonucleotide and could be 
modified to link macrocycles to the 3' end, or internal to an 
oligonucleotide. 
Incorporation during oligonucleotide synthesis (phos 
phate linkage): 
A monoprotected sapphyrin H-phosphonate was synthe 
sized for incorporation during oligonucleotide synthesis. A 
sapphyrin-conjugate was synthesized in a solid-phase 
manual oligonucleotide synthesizer via the H-phosphonate 
method. The oligonucleotide was assembled on a solid 
support such as controlled pore glass (CPG) by a cycle of 
steps. The 5' end of the growing oligonucleotide was depro 
tected, the reaction phase was neutralized, and the activated 
monoprotected nucleotide H-phosphonate was coupled at 
the 5' end of the oligonucleotide. Derivatized sapphyrin was 
incorporated at the 5' end of the oligonucleotide during the 
last step of the synthesis in place of a nucleotide. 
Specifically, the desired oligonucleotide was synthesized 
on a CPG solid support on a 0.2M scale. The derivatized 
sapphyrin was attached to the oligonucleotide on a manual 
oligonucleotide synthesizer (Cruachem PS 150 DNA Syn 
thesizer, Sterling, Va.). The synthesis was run under argon (5 
psi). Syringes were oven-dried and kept in a desiccator until 
use. The following sequence was used for coupling: 
1. Wash-acetonitrile-2 min. 
2. Deblock-3% dichloroacetic acid in methylene chlo 
ride-3 min. 
3. Wash-acetonitrile-2 min. 
4. Wash-acetonitrile/pyridine (1:1)-2 min. 
5. Couple-4 mM derivatized sapphyrin (1 eq) in meth 
ylene chloride and 65 mM pivaloyl chloride in acetonitrile/ 
methylene chloride (1:1)-30 L solution alternating for 1.5 
min 
6. Wait-15 min. 
7. Wash-acetonitrile, acetonitrile/pyridine (1:1), aceto 
nitrile-2 min, 1 min, 2 min. 
8. Deprotect-3% dichloroacetic acid in methylene chlo 
ride-3 min. 
9. Wash-acetonitrile, acetonitrile/pyridine (1:1)-2 min, 
2 min. 
10. Oxidize-0.1M iodine in water/pyridine/N-meth 
ylimidazole/THF (5/4/1/90), 0.1M iodine in water/triethy 
lamine/THF (5/5/90)-2 min, 2 min. 
11. Wash-acetonitrile/pyridine 
methanol-2 min, 1 min, 2 min. 
The conjugate attached to CPG was added to 2 mL conc. 
ammonium hydroxide for 4 h. The solution was filtered and 
the filtrate was evaporated to afford crude sapphyrin-oligo 
nucleotide conjugate which could be purified by fplc on a 
C3 column using acetonitrile/100 mM triethylammonium 
acetate pH 7.0. 
This method may be used to synthesize any type or length . 




end or in the interior of the oligonucleotide. Additionally, the 
oligonucleotide could be modified with multiple macro 
cycles. 
A further method for the synthesis of macrocycleoligo 
nucleotide conjugates is to incorporate nucleotides enzy 
matically. A variety of DNA and RNA polymerases may be 
used, however, the Klenow fragment of DNA polymerase I 
from E. coli and terminal deoxynucleotidyl transferase are 
preferred. Goodchild, J. (Bioconjugate Chemistry, 
1:165-187, 1990) provides a general discussion of the 
enzymatic synthesis of oligonucleotides and is incorporated 
by reference herein. 
EXAMPLE 7 
SELECTIVE DICARBOXYLATE TRANSPORT 
BY SAPPHYRIN DIMERS 
To illustrate the binding of dicarboxylate anions by sap 
phyrin dimers, transport studies were carried out utilizing a 
standard U-tube model membrane system. Transport experi 
ments were performed using a glass U-tube at 24-26°C. 
Conditions: Source phase: 1 mL of a 1:1:1 ratio of 4-nitro 
phthalic acid, 5-nitroisophthalic acid and nitroterephthalic 
acid (10 mM of each) at pH 7.2 (adjusted by the addition of 
NaOH). Membrane (6 mL); carrier (la or 23): 0.1 mM in 
dichloromethane. Receiving phase: 1 mL of HO, pH 7.0. 
The release of the dicarboxylate dianions into the receiving 
phase was monitored as a function of time via HPLC product 
analysis achieved using adenosine or uridine as the internal 
standards. In all cases, control experiments were performed 
in the absence of carrier. Error is within ti O%. 
It was found that at neutral pH, dimer 23 acts as an 
efficient carrier for a range of dicarboxylates, including 
various isomers of nitrobenzene (Table 3). Further, in direct 
competition experiments (made using 23), nitroterephthalate 
dianion was found to be transported three times faster than 
4-nitrophthalate dianion, suggesting a level of anion-based 
selectivity. On the other hand, none of the isomeric nitro 
phthalates was found to be transported effectively by the 
alkyl-substituted monomeric sapphyrin la. 
TABLE 3 
INITIAL RATES OF NTROBENZENE 
DICARBOXYLATE DANION TRANSPORT 
k (10 mol/cm, h) 
Carrier ortho leta para 
la 0.962 0.705 0.825 
23 2.90 2.926 6.803 
0.1 mM in dichloromethane. 
Aq (I): 10 mM in each of 4-nitrophthalic acid, 5-nitroisophthalic acid and 
nitroterephthalic acid at pH 7.2 (adjusted by NaOH); Aq (II): pH 7. 
EXAMPLE 8 
DICARBOXYLATE BINDING EFFICACY WITH 
A SAPPHYRIN DEMER 
Quantitative assessments of dicarboxylate binding effi 
cacy in methanol were made using standard spectroscopic 
techniques. In general, 'H NMR methods were employed, 
with the observed changes in the HNMR chemical shifts of 
the aromatic protons of the carboxyl-containing substrate 
(kept constant in the mM concentration range) being moni 
tored as a function of increased receptor concentration. In 
some instances, well-resolved shifts could not be observed 














spectroscopic titration procedures were used or deuterated 
substrates were employed such that the binding process 
could be followed by H NMR. 
More specifically, binding studies were effected by means 
of H NMR (General Electric QE-300), H NMR (Bruker 
AM-500) and Vis (Beckman DU 640) titrations and were 
carried out at 293 K. using methanol as the solvent. Metha 
nol-d was used for the HNMR titrations and non-deuter 
ated methanol was used for the H NMR analyses. For both 
sets of NMR titrations, the substrate concentration was held 
constant and the receptor concentration varied. The change 
in the chemical shifts of the aromatic hydrogen/deuterium 
atoms of the substrates were then followed and used as a 
way of monitoring, in a relative way, the concentration of the 
bound and unbound species. For the Vis titrations, the 
receptor concentration was held constant and the substrate 
concentration varied. There, the change in absorption of the 
Soret-like band of receptor 23 was followed. Receptor 23 
was used in the form of its bis-HCl salt, 23-2HCl. This salt 
was prepared by washing a dichloromethane solution of 23 
(in its free-base form) three times with independent portions 
of an aqueous pH 6 solution of HCl, followed by 1) drying 
over NaSO, 2) evaporative removal of solvent and 3) 
drying in vacuo. Substrates were used as their trimethylam 
monium salts. They were prepared by dissolving the relevant 
dicarboxylic acid in methanol and then bubbling with trim 
ethylamine gas for 10 min. The mixtures that resulted were 
evaporated to dryness on the rotor evaporator and then 
further dried under high vacuum. Terephthalic acid-d was 
purchased from Aldrich Chemical Co. Isophthalic acid-d 
was prepared according to a modification of a literature 
procedure: Lockley, W. J. S. J. Label. Comp. Radiopharm., 
1984, 21, 45-57. Results are given in Table 4. 
TABLE 4 
BNDING CONSTANTS FOR COMPLEXFORMATION 
BETWEEN RECEPTOR 23 AND WARIOUS 
DICARBOXYLATE SUBSTRATES (S) IN METHANOL 
AT 293 K 
S K(M) Selectivity 
Phthalate K = 310; K = 280 1.2 
Isophthalate 2400, 2500f 9.4 
5-Nitroisophthalate 5300f 20.4 
Terephthalate 4 600 17.7 
Nitroterephthalate 9 OOf 35.0 
Benzoate K, K = 1 380 5.6 
K, K = 530 
Oxalate 260f 1 
Malonate 450 1.7 
Sapphyrin dimer 23 was used as its bis HCl salt, 23-2HCl. Substrates (S) 
were used as their (CH)N H salts in order to prevent proton transfer to 23. 
Values of K in selected cases were measured by two, or more methods with 
complete internal agreement being found. 
Complexes of 1:1 stoichiometry (K-K) were formed unless otherwise 
noted. 
Relative to the worst bound substrate, oxalate. 
Determined by HNMR by titrating with receptor 23 while the concentration 
of the studied carboxylate ion was held constant at a value of 1-5 mM, 
depending on the measurement. 
Determined by H NMR by titrating with receptor 23 while keeping the 
concentration of the carboxylate anion constant at a value of 1-5 mM, 
depending on the measurement. 
Determined by Vis spectroscopy by titrating in increasing amounts of the 
studied carboxylate anions (from 1 x 10 to 1 x 10M) into a solution of 
receptor 23 (initial concentration between 1 x 10 and 5x 10M). 
The results in Examples 7 and 8 show that sapphyrin 
dimers can be both an excellent and an inherently selective 
receptor for dicarboxylate anions. Sapphyrin dimer 23, for 
instance, shows little affinity for monocarboxylate-derived 
substrates while showing very good affinities for certain 
dicarboxylates. Interestingly, dimer 23 also displays a pref 
erence for linear over bent substrates and aromatic over 
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aliphatic substrates that is remarkable given the inherently 
floppy nature of this receptor. 
EXAMPLE 9 
SAPPHYRIN MULTIMERS AS THERAPEUTIC 
AGENTS 
The discoveries embodied by the present invention may 
be advantageously exploited in further scientific research, 
and importantly, in the development of new methods and 
compositions for treating various human diseases including 
cancer. Sapphyrins and their multimers are envisioned to be 
of use in a wide variety of clinical embodiments, including 
the binding, delivery and cellular transport of nucleotide 
derivatives, such as antiviral agents and dicarboxylates. The 
sapphyrin-sugar derivatives have the added potential of 
more specific cellular targeting according to sugar recogni 
tion by specific receptors. Sapphyrins and multimeric sap 
phyrins also have potential for use directly as chemothera 
peutics. 
Sapphyrin multimers also be used as a delivery agent for 
the intracellular targeting of any drug that has a phosphate 
group. Of course, given the synthetic methodology disclosed 
herein, it is contemplated that the sapphyrin multimers may 
be derivatized by the introduction of further groups to the 
periphery of the macrocycles, which groups would add the 
specificity and/or selectivity of the sapphyrin multimer-drug 
interaction. Sapphyrin multimer-drug interactions of this 
sort may be based upon either non-covalent interactions, or 
alternatively, may employ a covalent bond that is cleaved on 
exposure to the intracellular environment. 
In particular embodiments, oligomers or polymers of 
sapphyrin or sapphyrin-nucleobase conjugates are envi 
sioned to be of use in antisense technology. Such polymers 
will be of use both in the delivery and transport of oligo 
nucleotides, and in enhancing their effectiveness once inside 
the target cell. The enhancing effect is based upon the 
properties of sapphyrin in binding to the phosphate portions 
of nucleic acids. This property will increase the affinity of 
the antisense construct for its target, and reduce diffusion 
which generally limits the effectiveness of an antisense 
molecule. This dual transport and binding role of sapphyrin 
oligonucleotide conjugates in antisense treatments is par 
ticularly advantageous in that no other method or combina 
tion of methods available have a DNA (or RNA) affinity 
component. 
The interaction between sapphyrin multimers and DNA, 
in which sapphyrin acts as a chelate for the phosphate 
backbone of DNA, is particularly important. The binding 
constant of unmodified sapphyrin for DNA has been deter 
mined to be on the order of 10M, and evidence shows that 
the mode of DNA binding is not intercalation or groove 
binding. The inventors will extend these findings and con 
struct, using all the available experimental evidence, com 
puter models of the sapphyrin-DNA interaction. These mod 
els will allow the design and engineering of covalently 
linked multimeric sapphyrin molecules with increased affin 
ity and specificity. 
These second generation multimeric sapphyrin-based 
constructs should have a DNA affinity high enough to 
interfere with biological processes such as transcription and 
translation. It is contemplated that this will ultimately lead 
to the development of sapphyrin-based therapeutic agents 














Sapphyrin multimers themselves are also contemplated 
for use directly as chemotherapeutic agents. Currently avail 
able chemotherapeutics generally have complex structures, 
or complicated modes of interaction with their targets, that 
preclude systematic improvement. The development of a 
novel class of DNA binding compounds, namely the sap 
phyrin multimers of the present invention, therefore pro 
vides important opportunities for the development and use 
of novel therapeutic agents. 
Due to the unique mode of sapphyrin-DNA interaction, 
the sapphyrin multimer possesses an unrivaled ability to act 
as a general DNA binding platform. Binding can also be 
modified so as to adjust both target cell specificity and 
degree of interaction with the DNA. For sapphyrins, impor 
tantly, the basic site of interaction with the DNA involves the 
interior of the sapphyrin macrocycle, so that the exterior 
positions R'-R' can be substantially modified without 
significantly disrupting the DNA binding interaction. These 
exterior positions can be used to systematically adjust fea 
tures such as solubility, membrane permeability and cell 
selectivity. Furthermore, groups designed to modulate inter 
action with DNA can be attached to the exterior of the 
sapphyrins including alkylating functions (bromoacetamido 
groups, epoxides etc.) to provide covalent attachment to 
DNA or ene-diyne moieties to allow for double stranded 
DNA cleavage. 
Sapphyrin multimers that bind to DNA simultaneously 
strengthen the entire interaction. This feature allows a modu 
lar approach in which the appropriate number (2-10) of 
sapphyrin molecules is attached in a single molecule, per 
haps with different sapphyrin units containing sapphyrin 
derivatives with different groups attached that control such 
important properties such as solubility, target cell specificity 
and DNA modification ability. 
While the compositions and methods of this invention 
have been described in terms of preferred embodiments, it 
will be apparent to those of skill in the art that variations may 
be applied to the composition, methods and in the steps or 
in the sequence of steps of the method described herein 
without departing from the concept, spirit and scope of the 
invention. More specifically, it will be apparent that certain 
agents which are both chemically and physiologically 
related may be substituted for the agents described herein 
while the same or similar results would be achieved. All 
similar substitutes and modifications apparent to those 
skilled in the art are deemed to be within the spirit, scope and 
concept of the invention as defined by the appended claims. 
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What is claimed is: 
1. A sapphyrin multimer having structure I: 
R2 Ri R10 R9 I 
R5 R6 
wherein each of R'-R'' are independently hydrogen, alkyl, 
alkene, alkyne, halide, alkylhalide, hydroxyalkyl, hydroxy 
alkylamido, glycol, polyglycol, thiol, thioalkyl, aminoalkyl, 
carboxyalkyl, carboxyamidealkyl, oxyalkyl, alkoxyalkyl, 
aryloxyalkyl, oxyhydroxyalkyl, alkyloxycarbonyl, aryloxy 
carbonyl, aldehyde, ether, ketone, carboxylic acid, phos 
phate, phosphonate, saccharide, nucleobase, sulfate, phos 
phate substituted alkyl, phosphonate substituted aly Ot 
sulfate substituted alkyl; wherein at least one of R-R'is of 
the formula (CH)-A-(CH2)-B, where 
A is alkyl, oxy, sulfide, amide, carbonyl, alkenyl, alkynyl, 
aryl, alkylhalide, hydroxyalkyl, glycol, polyglycol, 
alkylthiol, substituted alkyl, phosphate, phosphonate, 
sulfate, phosphate substituted alkyl, phosphonate sub 
stituted alkyl, sulfate substituted alkyl, carbonate, car 
bamate, bis(aminoguanidinium), carboxy, carboxya 
mide, carboxyamidealkyl, carboxyamidearyl, thiol 
substituted carboxyamide, O derivatized 
carboxyamide; 
B is a sapphyrin, or a sapphyrin derivative, or an oligomer 
or polymer of sapphyrin or of a sapphyrin derivative 
having up to about 200 sapphyrin units, and 
n and m are independently an integer from 0 to 10. 
2. The sapphyrin multimer of claim 1 wherein A is 
carboxyanidearyl; B is a sapphyrin or a Sapphyrin deriva 
tive; and n and m are independently 1, 2 or 3. 
3. The sapphyrin multimer of claim 1 wherein A is 
carboxyamidealkyl; B is a sapphyrin or a sapphyrin deriva 
tive; and n and m are independently 1, 2 or 3. 
4. The sapphyrin multimer of claim 3 wherein B is a 
sapphyrin derivative and the sapphyrin derivative is 
hydroxyalkyl, saccharide or aminosaccharide derivative. 
5. The sapphyrin multimer of claim 1 wherein A is 
carboxyamidealkyl bound to a further amide; and the further 
amide is covalently bound to two molecules of B to form a 
tethered sapphyrin trimer. 
6. The sapphyrin multimer of claim 1 wherein B is a 
sapphyrin or sapphyrin derivative and B is further bound to 
a third sapphyrin or sapphyrin derivative to form a linear 
sapphyrin trimer. 
7. The sapphyrin multimer of claim 6 wherein the linear 
sapphyrin trimer is covalently bound to form a cyclic trimer. 
8. The sapphyrin multimer of claim 1 wherein A is 
carboxyamidealkyl bound to a further amide; the further 
amide being covalently bound to a second sapphyrin and a 
linker, the linker being bound to a third and a fourth 
sapphyrin to form a tethered sapphyrin tetramer. 
9. The sapphyrin multimer of claim 8 wherein the linker 
is a tertiary amine. 
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10. The sapphyrin multimer of claim 1 wherein B is an 
oligomer or polymer of sapphyrin or sapphyrin derivative. 
11. The sapphyrin multimer of claim 10 where B is a 
polymer of sapphyrin or sapphyrin derivative having from 4 
to about 200 sapphyrin units. 
12. The sapphyrin multimer of claim 9 wherein A is 
phosphate. 
13. The sapphyrin multimer of claimt wherein at least one 
of R-R' is a nucleobase. 
14. The sapphyrin multimer of claim 13 where B is a 
sapphyrin derivative and the derivative is a nucleobase. 
15. The sapphyrin multimer of claim 11 wherein B is a 
polymer of sapphyrin derivative and the derivative is a 
nucleobase. 
16. The sapphyrin multimer of claim 15 further compris 




17. A sapphyrin multimer having structure 14, 15, 15b, 
15c, 19, 21, 22, 23, 24, 25, 26, 27, 34, 35, or 36. 
18. A method of making a sapphyrin multimer comprising 
the steps of 
obtaining a sapphyrin or sapphyrin derivative, and 
reacting the sapphyrin or sapphyrin derivative with a 
further sapphyrin or sapphyrin derivative to form a 
sapphyrin multimer. 
19. A method of binding an anion comprising the step of 
contacting the anion with a multimeric sapphyrin or sap 
phyrin derivative. 
20. The method of claim 19 where the anion is a phos 
phate anion or a dicarboxylate anion. 
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